scholarly journals Characterization of the Immune Response Induced by a Commercially Available Inactivated Bluetongue Virus Serotype 1 Vaccine in Sheep

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Ana Cristina Pérez de Diego ◽  
Pedro José Sánchez-Cordón ◽  
Ana Isabel de las Heras ◽  
José Manuel Sánchez-Vizcaíno

The protective immune response generated by a commercial monovalent inactivated vaccine against bluetongue virus serotype 1 (BTV1) was studied. Five sheep were vaccinated, boost-vaccinated, and then challenged against BTV1 ALG/2006. RT-PCR did not detect viremia at any time during the experiment. Except a temperature increase observed after the initial and boost vaccinations, no clinical signs or lesions were observed. A specific and protective antibody response checked by ELISA was induced after vaccination and boost vaccination. This specific antibody response was associated with a significant increase in B lymphocytes confirmed by flow cytometry, while significant increases were not observed in T lymphocyte subpopulations (CD4+, CD8+, and WC1+), CD25+regulatory cells, or CD14+monocytes. After challenge with BTV1, the antibody response was much higher than during the boost vaccination period, and it was associated with a significant increase in B lymphocytes, CD14+monocytes, CD25+regulatory cells, and CD8+cytotoxic T lymphocytes.

Vaccine ◽  
2010 ◽  
Vol 28 (13) ◽  
pp. 2522-2531 ◽  
Author(s):  
Channakeshava Sokke Umeshappa ◽  
Karam Pal Singh ◽  
Awadh Bihari Pandey ◽  
Rabindra Prasad Singh ◽  
Roopa Hebbandi Nanjundappa

Author(s):  
Gcwalisile B. Zulu ◽  
Estelle H. Venter

Bluetongue (BT) is a non-contagious disease of sheep and other domestic and wild ruminants caused by the bluetongue virus (BTV). Currently 26 serotypes of the virus have been identified. In South Africa, 22 serotypes have been identified and BT is controlled mainly by annual vaccinations using a freeze-dried live attenuated polyvalent BTV vaccine. The vaccine is constituted of 15 BTV serotypes divided into three separate bottles and the aim is to develop a vaccine using fewer serotypes without compromising the immunity against the disease. This study is based on previously reported cross-neutralisation of specific BTV serotypes in in vitro studies. Bluetongue virus serotype 4 was selected for this trial and was tested for cross-protection against serotype 4 (control), 1 (unrelated serotype), 9, 10 and 11 in sheep using the serum neutralisation test. The purpose of the study was to determine possible cross-protection of different serotypes in sheep. Of those vaccinated with BTV-4 and challenged with BTV-1, which is not directly related to BTV-4, 20% were completely protected and 80% showed clinical signs, but the reaction was not as severe as amongst the unvaccinated animals. In the group challenged with BTV-10, some showed good protection and some became very sick. Those challenged with BTV-9 and BTV-11 had good protection. The results showed that BTV-4 does not only elicit a specific immune response but can also protect against other serotypes.


2020 ◽  
Vol 7 ◽  
Author(s):  
Andrei Koltsov ◽  
Sodnom Tsybanov ◽  
Andrey Gogin ◽  
Denis Kolbasov ◽  
Galina Koltsova

Virology ◽  
1990 ◽  
Vol 177 (1) ◽  
pp. 396-400 ◽  
Author(s):  
H. Takamatsu ◽  
J.N. Burroughs ◽  
A.M. Wade-Evans ◽  
P.P.C. Mertens

Sign in / Sign up

Export Citation Format

Share Document